Clinically,drugs available for oral cancer patients are mainly designed to target EGFR[15-17]; however, mutations of the EGFR downstream effectors andresistance to said drugs have been reported in some patients [5]. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.